DHEA Against Vaginal Atrophy - Safety Study of 12 Months

Completed · Phase 3

Conditions studied: Vaginal Atrophy

In brief

The purpose of this Phase III trial is to assess the long-term safety of intravaginal dehydroepiandrosterone (DHEA) in non-hysterectomized postmenopausal women with vaginal atrophy aged 40 to 75 years.

Key facts

Study ID
NCT01256671
Run by
EndoCeutics Inc.
People needed
530
Starts
2010-12-01
Expected to finish
2012-12-01
Last updated by the study team
2017-10-18

Who can join

Age: 40 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.